Latest news

Phase 1-2

Inhibrx provides clinical update on ozekibart in late line colorectal cancer

Inhibrx Biosciences, a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, has released updated interim data from its phase 1/2 study evaluating ozekibart (INBRX-109) in combination with Folfiri in patients with locally advanced or metastatic, unresectable...
Funding & Finance

US$ 8.5 million investment in malaria and other R&D projects planned among pharma giants

The global health innovative technology (GHIT) fund has announced a total investment of approximately JPY 1.37 billion (US$ 8.5 million) in five R&D projects for the development of drugs for malaria and neglected tropical diseases (NTDs). Investment of around...
Phase 1-2

Positive phase 1 data for RAG-17 in amyotrophic lateral sclerosis patients with mutations in the superoxide dismutase 1 gene

Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on developing next-generation RNA-based medicines, has announced positive preliminary data from the single ascending dose (SAD) phase 1 portion of its ongoing Phase I/II clinical trial of RAG-17. RAG-17 is a novel...
CRO

New non-compromise early-phase progression accelerator launched

Carbogen AMCIS introduces Sprint for early-phase development, a new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour. Sprint has been designed to deliver faster, more efficient progression to clinical phases without compromising scientific rigour. As pressure on...
Phase 3

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting its first primary endpoint. In the phase 3 I can study (NCT06291376), patients with immunoglobulin A nephropathy (IgAN) treated...
Phase 1-2

Tenvie doses first subject in phase 1 TNV108 trial for peripheral neuropathies

Tenvie Therapeutics has dosed the first participant in its phase 1 clinical trial of TNV108 to treat peripheral neuropathies. The trial will assess the tolerability and safety of single and multiple ascending TNV108 doses in healthy volunteers. As a first-in-human...
Phase 3

Roche reports phase 3 study results for myelin oligodendrocyte glycoprotein antibody-associated disease

Roche has reported new findings from the phase 3 meteoroid trial of Enspryng (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The double-blind, randomised, multi-centre, placebo-controlled trial revealed that Enspryng reduced the risk of a...
Conferences and Events

Interphex Week Tokyo 2026 organises show floor around manufacturing, packaging, inspection and digital production technologies

Interphex Week Tokyo 2026 will take place from 20-22 May at Makuhari Messe, bringing together six specialised exhibitions and a concurrent regenerative medicine expo covering pharmaceutical and cosmetics manufacturing, ingredients, laboratory and quality technologies, digital transformation, biopharma, and...
Commercial

Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell thermal cyclers

Bio-Rad Laboratories has launched the PTC Harmony Thermal Cycler line, designed to offer broader access to optimised workflows for PCR applications such as sequencing, cloning, and genotyping. PTC Harmony 96 and PTC Harmony Deepwell are the latest additions to...
Funding & Finance

Evotec announces chief financial officer transition

Evotec SE has announced that chief financial officer (CFO) Paul Hitchin will step down on 30 April 2026 for personal reasons unrelated to the company. The supervisory board has accepted Mr Hitchin’s decision and expressed deep appreciation for his...
CDMO

PCI Pharma Services announces US$1 billion expansion of US sterile fill-finish and drug-device delivery combination capabilities

PCI Pharma Services, a world-leading integrated global contract development and manufacturing organisation (CDMO) focused on innovative biologic and small molecule therapies, has announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug...
Discovery

ImmunoForge to accelerate central nervous system drug development with innovative blood-brain barrier shuttle platform

ImmunoForge, a clinical-stage biopharmaceutical company specialising in treatments for rare and muscular diseases, is poised to redefine central nervous system (CNS) drug delivery with its proprietary LMT15 Platform, a next-generation blood-brain barrier (BBB) shuttle technology. The LMT15 Platform is based on...
Phase 3

Novo Nordisk to seek oral sickle cell therapy approval after phase 3 success

A phase 3 trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC) and increasing haemoglobin (Hb) response in patients with sickle cell disease (SCD). In the pivotal hHibiscus trial (NCT04624659), the etavopivat arm...
Conferences and Events

AI Drug Discovery & Development Summit (AIDDD)

27-29 October 2026 Boston Marriott Copley Place, Boston, USA The AI Drug Discovery & Development Summit (AIDDD) is the meeting place for the innovators redefining how medicines are discovered and developed. Bringing together leaders from pharma, biotech, AI, and academia, the...
Conferences and Events

Global Drug Delivery and Formulation (DDF) Summit

18-20 May Berlin, Germany The Global Drug Delivery and Formulation (DDF) Summit is Europe’s premier gathering for professionals at the forefront of pharmaceutical development and drug delivery science. Now in its 17th year, the Summit has earned a reputation for delivering exceptionally...
Conferences and Events

Chemspec Europe reveals new details about 2026 conference programme

6–7 May 2026 Koln, Germany Chemspec Europe has unveiled further details of its highly anticipated conference programme, offering attendees fresh insight into the key themes, sessions and new interactive formats shaping this year’s event. Taking place on 6–7...
Phase 1-2

Dayspring Pharma announces phase 2 trial of CG2001 foam met primary endpoint in Chinese adult men with androgenetic alopecia

Dayspring Pharma has announced top-line data from its phase 2 clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results, with a favourable...
Funding & Finance

PlaqueTec secures $5 million financing to advance drug discovery

PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to identify inflammatory drivers of cardiovascular disease (CVD), has raised $5 million. The oversubscribed financing round was funded entirely by the company’s existing investor base. The investment will support the continued build-out...
Commercial

Expanded antibody portfolio enhances detection of biologics and therapeutics for bioanalytical applications

Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, has extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa),...
Phase 3

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

AstraZeneca plans to seek accelerated approval of Ultomirisin kidney disease after the drug showed benefit after just 34 weeks, meeting its first primary endpoint. In the phase 3 I can study (NCT06291376), patients with immunoglobulin A nephropathy (IgAN) treated...
Phase 1-2

Tenvie doses first subject in phase 1 TNV108 trial for peripheral neuropathies

Tenvie Therapeutics has dosed the first participant in its phase 1 clinical trial of TNV108 to treat peripheral neuropathies. The trial will assess the tolerability and safety of single and multiple ascending TNV108 doses in healthy volunteers. As a first-in-human...
Phase 3

Roche reports phase 3 study results for myelin oligodendrocyte glycoprotein antibody-associated disease

Roche has reported new findings from the phase 3 meteoroid trial of Enspryng (satralizumab) in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The double-blind, randomised, multi-centre, placebo-controlled trial revealed that Enspryng reduced the risk of a...
Discovery

IRBM reports progress in drug discovery for Zika virus

IRBM, a leader in early drug discovery research, recently announced a major scientific breakthrough with the discovery of a new and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The results, published in Nature Communications, demonstrate the...
Discovery

Sofetabart mipitecan receives ‘Breakthrough Therapy’ designation for the treatment of certain patients with platinum-resistant ovarian cancer

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine,...
Phase 1-2

Preliminary AMT-191 phase 1/2a data shows sustained increases in α-Gal A enzyme activity in patients with Fabry Disease

uniQure has announced updated preliminary safety and exploratory efficacy data from 11 patients in its phase 1/2a trial of AMT-191, an investigational AAV gene therapy for the treatment of Fabry disease. The updated data was presented at the WORLDSymposium in San...
- Advertisement -
EPO Summit ad
- Advertisement -
Pharmconex ad
- Advertisement -
NLS Days ad
- Advertisement -
ILMAC ad
- Advertisement -
BIO Europe
- Advertisement -spot_img
- Advertisement -spot_img

MOST POPULAR POSTS

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Menu

© Web design by Social Media Services 2026. All rights reserved.